Kuripenta-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed to manage gastrointestinal disorders characterized by acid reflux, heartburn, and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the tone of the lower esophageal sphincter and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. The synergistic action of these two agents in Kuripenta-DSR Capsule offers comprehensive management of upper gastrointestinal symptoms by addressing both motility and acid secretion abnormalities. This combination is typically prescribed for patients requiring rapid symptom relief and improved gastric function. Kuripenta-DSR should be used under medical supervision, considering contraindications such as hypersensitivity to its components, and potential drug interactions. Adherence to prescribed dosage and duration is essential to optimize therapeutic outcomes and minimize adverse effects.